In the WHO classification subcutaneous panniculitis-like T-cell lymphoma (SPTL) is defined as a distinct type of T-cell lymphoma with an aggressive clinical behaviour. Recent studies suggest that distinction should be made between SPTL with an α /β T-cell phenotype (SPTL-AB) and SPTL with a γ δ -T-cell phenotype (SPTL-GD), but studies are limited. To better define their clinicopathologic features, immunophenotype, treatment, and survival, 63 SPTL-AB and 20 SPTL-GD, were studied at a workshop of the EORTC Cutaneous Lymphoma Group.
INTRODUCTION
In 1991, Gonzales et al. described a new type of T-cell lymphoma with clinicopathologic features simulating a panniculitis, which was often associated with a hemophagocytic syndrome (HPS) and an aggressive clinical course 1 . Under the term subcutaneous panniculitis-like T-cell lymphoma (SPTL) this new condition was included as a provisional entity in the REAL classification 2 and in the EORTC classification for primary cutaneous lymphomas 3 , and subsequently as a distinct disease entity in the WHO classification 4 .
In recent years there is increasing evidence that within the group of SPTL distinction should be made between cases with an α /β T-cell phenotype (SPTL-AB) and cases with a γ δ -T-cell phenotype (SPTL-GD) 5, 6 . While SPTL-AB generally have a CD4-, CD8+, CD56-phenotype and a favorable prognosis, SPTL-GD typically have a CD4-, CD8-T-cell phenotype with frequent coexpression of CD56, and a poor prognosis [7] [8] [9] [10] [11] [12] . Based on these observations, in the WHO-EORTC classification for cutaneous lymphomas the term SPTL is only used for SPTL-AB, whereas SPTL-GD are included in the group of cutaneous γ δ -T-cell lymphomas (CGD-TCL). This group is included as a provisional entity within the broad category of peripheral T-cell lymphoma, unspecified 13 .
It should be emphasized that this subdivision of SPTL into two distinct groups is based on only few studies and still needs further confirmation. Evaluation of existing literature, which mainly concerns case reports, small case series and reviews [5] [6] [7] [8] [9] [10] [11] [12] [14] [15] [16] [17] [18] [19] [20] [21] , is hampered seriously by lack of complete immunophenotypical data and/or inclusion of malignant lymphomas with predominant subcutaneous involvement other than SPTL 8 . This subdivision of SPTL may also have major therapeutic consequences. At present, in most centers all SPTL are routinely treated with doxorubicin-based multi-agent chemotherapy 21 . Whether this is the best treatment for patients with SPTL-AB may however be questioned.
The present report describes the results of a workshop of the EORTC Cutaneous Lymphoma
Group, in which clinical, histological and immunophenotypical data of 63 SPTL-AB and 20 SPTL-GD were compared. The aims of this study were: 1. to confirm that SPTL-AB and SPTL-GD are indeed distinct entities; 2. to establish more precisely the clinicopathologic features, immunophenotype, response to treatment, prognostic factors and survival of these two groups of SPTL, and 3. to find out which cases should be treated with aggressive therapies and which with non-aggressive (immunosuppressive) therapies.
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MATERIAL AND METHODS
A workshop of the EORTC Cutaneous Lymphoma Task Force was held on January [19] [20] [21] 2007 at the Leiden University Medical Center (Leiden, The Netherlands). Participants were experienced hematopathologists, dermatopathologists and dermatologists from 8 European cutaneous lymphoma centers. Cases solicited for were SPTL, as defined in the WHO classification 4 , thus including both SPTL-AB and SPTL-GD. Only cases adequately staged and with follow-up data available were included. Staging included physical examination, complete and differential blood cell counts, serum biochemistry, computed tomography scan of chest and abdomen and a bone marrow biopsy. Before the meeting completed data sheets containing information on a large number of clinical and histological parameters and in most cases routine HE sections, relevant immunostainings and unstained sections or paraffin blocks were submitted.
If not performed before, additional stainings were completed in the Department of Pathology, Leiden University Medical Center prior to the meeting. Immunostainings had been performed using antibodies against T-cell antigens (CD2, CD3, CD4, CD5, CD7, CD8, CD30, CD56, CD45RO, CD45RA, betaF1, TCRδ-1), B-cell antigens (CD20, CD79a), cytotoxic proteins (granzyme B, TIA-1, perforin), histiocytes (CD68) and the proliferation marker Mib-1.
Expression of immunostainings was scored as follows -: <25% , -/+: 25-50%. +/-: 51-75%, and +:
>75% of the neoplastic cells positive. In most cases, results of in situ hybridization for EBVencoded small RNA (EBER) and T-cell receptor (TCR) gene rearrangement analyses were available as well.
During the workshop H&E stained sections and immunostainings of all submitted cases were studied together behind a 23-headed microscope and classified by consensus using the criteria of the WHO-EORTC classification. A total number of 115 biopsies from 95 cases were available for evaluation. During the workshop 5 cases were excluded because a diagnosis of benign panniculitis was considered more likely. Another 7 cases were excluded because of insufficient immunophenotyping or incomplete follow-up data. The final study group included 83 cases.
Clinical and/or histological data of 34 of these cases have been part of previous studies 6, 7, 8, 11, 18, 20 .
Statistical analysis
Overall survival was calculated from the date of histologically confirmed diagnosis until the patient's death or last follow-up without an event. Disease specific survival was calaculated from the date of diagnosis until death from lymphoma or last follow-up without an event. Survival curves were estimated using the method of Kaplan and Meier and statistical comparison between 
RESULTS
Based on clinical, histological, immunophenotypical and molecular diagnostic data 63 cases were classified as SPTL-AB and 20 cases as SPTL-GD following the criteria of the WHO-EORTC classification. 13 The main clinical, histological and immunophenotypical data of these two groups are summarized in Tables 1 and 2 and will be described in more detail below.
SPTL with an alpha/beta T-cell phenotype (SPTL-AB)

Clinical characteristics
The group of SPTL-AB consisted of 21 males and 42 females. The median age at diagnosis was 36 years (range 9-79 years). Twelve of 63 (19%) patients were 20 years or younger. The duration of skin lesions before diagnosis ranged from 1 month to more than 10 years (median, 7 months).
All patients presented with typical nodular skin lesions or deeply seated plaques, which varied in diameter from one to over 20 cm, and sometimes left areas of lipoatrophy after disappearance ( Figure 1A ). Most patients presented with generalized skin lesions involving the legs (45 cases), the arms (39 cases) and/or the trunk (35 cases), and less commonly the face (16 cases 
Histology and immunophenotype
All cases showed a predominantly subcutaneous atypical lymphoid infiltrate, showing typical adipotropism and characteristically involving the fat lobules resembling a lobular panniculitis.
Septal involvement was generally mild or absent and appeared secondary. Mild to moderate extension of the atypical infiltrate into the reticular dermis, surrounding and occasionally infiltrating sweat glands and sometimes hair follicles and sebaceous glands was often observed.
However, infiltration of the superficial dermis and epidermis was seen in only 2 cases. with small reactive lymphocytes and many histiocytes, which were frequently vacuolated because of ingested lipid material. However, multinucleated giant cells were uncommon and well-defined granulomas were observed in only a minority of cases. Neutrophils and eosinophils were generally absent, apart from accumulating neutrophils in necrotic foci in some cases. In most cases plasma cells were rare. However, in 7 cases considerable proportions of plasma cells were noted. Interestingly, 6 of these seven cases were either associated with LE or had been misinterpreted as LE panniculitis in the past.
In all cases the neoplastic cells had the phenotype of CD3+, CD8+, CD4-T-cells, which strongly expressed cytotoxic proteins (granzyme B; TIA-1; perforin), and which showed loss of CD2, CD5 and/or CD7 in 10%, 50% and 44% of cases, respectively. Staining for CD45RA and CD45RO had been performed in a minority of cases, and consistently showed expression of CD45RO and negative staining for CD45RA. CD30 was always negative, while CD56 was expressed by the minority of neoplastic T-cells in only one of 61 cases studied. Staining for betaF1 was positive in all cases investigated (57/57) confirming the alpha/beta T-cell phenotype.
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Staining for TCRδ-1 on frozen sections had been performed in only 10 cases, and was always negative. Mib-1 staining showed a high proportion of proliferating cells, which characteristically concentrated around fat cells. In only 6/53 cases less than 25% of the neoplastic T-cells stained for Mib-1. In situ hybridization for EBV (EBER) had been performed in 38 cases and was always negative. Clonal rearrangements of the TCR beta and gamma genes had been documented in 9 of 9 and 28 of 36 cases investigated.
Therapy and follow-up data
Initial treatment at the time the diagnosis SPTL was made varied widely from only surgery or radiotherapy to doxorubicin-based chemotherapy followed by autologous stem cell transplantation (auto-SCT). In two patients, the skin lesions had disappeared spontaneously and no further treatment was given. In one patient who died of the complications of HPS initial treatment was unknown.
Thirty-one patients received CHOP or CHOP-like courses as initial treatment, in four of them combined with alemtuzumab (A-CHOP), and in three other patients directly followed by an auto- 
SPTL with a gamma/delta T-cell phenotype (SPTL-GD)
Twenty of 83 cases were classified as SPTL-GD. In 6 of 20 cases the diagnosis was supported by a positive staining for TCRδ-1 on frozen sections. In the other 14 cases, for which no frozen material was available, definite proof for a gamma/delta T-cell origin was lacking. However, since the neoplastic cells showed a negative staining for betaF1, while admixed reactive T-cells were betaF1 positive, a diagnosis of SPTL-GD was considered most likely. 13 
Clinical characteristics
The group of CGD-TCL consisted of 7 males and 13 females. The median age at diagnosis was 59 years (range 13-79 years). All patients presented with nodular or plaque-like lesions simulating a panniculitis, while 9 patients had ulcerating lesions at presentation (Figure 3 
years for rheumatoid arthritis. All but six patients had presented with systemic symptoms, lymphadenopathy, hepatosplenomegaly, cytopenias and/or elevated liver function tests. Bone marrow examination showed histiocytic hyperplasia, hemophagocytosis or decreased cellularity in 7 cases, but no evidence of lymphoma. A HPS was diagnosed in 9 of 20 patients, and was fatal in 7 of them.
Histology and immunophenotype
All cases showed a predominantly subcutaneous infiltrate as in SPTL-AB, but in many cases the upper dermis and the epidermis were infiltrated as well by a population of generally mediumsized pleomorphic T-cells (Figures 4 A and 4B ). In the upper dermis the neoplastic cells were localized around blood vessels and scattered between collagen bundles, in some cases associated with prominent edema ( Figure 4C ). Infiltration of the epidermis varied from few scattered cells in the basal layers to a marked lichenoid infiltrate with extensive necrosis of keratinocytes and ulceration. Angioinvasion and angiodestruction were commonly seen. Compared to SPTL-AB, the subcutaneous infiltrates tended to be more monotonous and diffuse, and preferential accumulation around individual fat cells (rimming) was less pronounced. In most cases a considerable admixture with histiocytes was observed. Apoptosis and necrosis were common and sometimes extensive.
Immunophenotypically, 17 cases had a CD3+, CD4-, CD8-phenotype, 2 cases a CD3+, CD4-, CD8+ phenotype and one case a CD3+, CD4+, CD8-T-cell phenotype. In all cases strong expression of cytotoxic proteins (granzyme B; TIA-1; perforin) was observed. CD56 was expressed in 12 of 20 cases. In three cases a significant proportion of the neoplastic cells were CD30 positive. Staining for TCRδ-1 on frozen sections was positive in all six cases tested. In all 20 cases the neoplastic cells were negative for betaF1. From the 14 cases in which TCRδ-1 staining was not performed, but which were betaF1 negative, 6 cases had a CD4-, CD8-, CD56+ phenotype, 6 cases a CD4-, CD8-, CD56-phenotype, one case a CD4-, CD8+, CD56+ phenotype and one case a CD4+, CD8-, CD56-phenotype. In situ hybridization for EBV (EBER) had been performed in 16 cases and was consistently negative.
Therapy and follow-up data
Fourteen of 20 patients were treated with multi-agent chemotherapy, generally CHOP or CHOPlike courses, in 3 of them preceded by short courses of prednisone, and in one followed by an auto-SCT. In only three of 14 cases, including the patients treated with an auto-SCT a complete The remaining five patients died before proper treatment could be initiated, 1 to 6 months after diagnosis. During follow-up 7 patients developed visceral disease, involving liver, lungs, kidney, CNS and oral mucosa. At the time of last follow-up (median follow-up, 12 months; range 1-108 months), 15 of 20 patients had died of HPS and/or progressive lymphoma, one was still alive with progressive disease, and four patients were in complete remission 4, 12, 38 and 108 months after diagnosis, respectively. The 2-year and 5-year OS were 31% and 11%, respectively. (Fig. 2B) . In these SPTL-GD no significant differences in survival were found between cases with and without HPS, neither between CD56-positive and CD56-negative cases (data not shown).
DISCUSSION
In the present study 83 SPTL as defined in the WHO classification were reviewed by a multidisciplinary group of hematopathologists, dermatopathologists and dermatologists collaborating within the EORTC Cutaneous Lymphoma Group. The results of this study confirm that SPTL-AB and SPTL-GD represent distinct clinicopathologic entities [5] [6] [7] [8] . The main distinguishing features between both conditions are summarized in Table 3 . Our results justify the terminology and definitions of the new WHO-EORTC classification, in which the term SPTL is only used for the former group, while the latter are included in the group of CGD-TCL, which represents a provisional entity in the broad category of PTL, unspecified 13 .
The results of our study do not only show clearcut differences between SPTL-AB and SPTL-GD, but also between SPTL-AB with and those without an associated HPS. In contrast, in the group of SPTL-GD no difference in survival was found between patients with and patients without HPS. Patients with SPTL-GD also proved highly resistant to multi-agent chemotherapy, and had an extremely poor prognosis, irrespective of the presence of a HPS or expression of CD56.
Nevertheless, three of the four patients still alive did not have a HPS. One of these three patients
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In line with previous studies SPTL-AB were always negative for EBV 5, 7, 8 . Staining for EBV may therefore be a valuable adjunct in differentiating SPTL from extranodal NK/T-cell lymphoma, nasal type, which may sometimes also present with prominent subcutaneous involvement 7, 8 .
Apart from SPTL-GD and other aggressive T-cell lymphomas, SPTL-AB should be differentiated from lupus erythematosus panniculitis (LEP). The relationship between SPTL and LEP, which may be clinically indistinguishable, is controversial 27, 28 . In a detailed report on 11 cases of LEP, features between LEP and SPTL and suggested that both conditions form a spectrum of disease 27 .
The present study group contained four SPTL patients with a definitive diagnosis of LE. In addition, at least four patients with SPTL had initially been misinterpreted as lupus panniculitis.
These numbers might even be higher, since LE history and serology data had not specifically been asked for. Interestingly, these patients with a concurrent or prior diagnosis of LE often showed a considerable admixture with CD4+ T-cells and plasma cells not observed in the other SPTL cases. In these cases a diagnosis of SPTL-AB had finally been made, because of the presence of cellular atypia in combination with loss of pan-T-cell markers and/or the presence of clonal TCRγ gene rearrangements. These observations suggest overlapping features between SPTL and LEP in a small proportion of cases, and suggest that all patients with suspected SPTL should be screened for LE. Moreover, in particular in these cases systemic steroids are the preferred mode of treatment, and systemic chemotherapy should not be considered as first option.
A recent report describes a patient with SPTL-GD (CGD-TCL), who presented with skin lesions clinically and histologically resembling LEP, but who had an aggressive clinical course 29 . This and other cases 30 underline that combination of clinical features, histopathology, immunophenotyping and molecular analysis as well as repeat biopsies are essential to differentiate between LEP and malignant lymphomas involving the subcutis.
In conclusion, the results of the present study confirm that SPTL-AB and SPTL-GD are distinct entities, and justify that the term SPTL should further only be used for SPTL-AB, while SPTL-GD should now be classified as CGD-TCL. SPTL-AB without associated HPS has an excellent prognosis. There is sufficient reason to question whether CHOP (or in some centers even A-CHP)
should be the first choice of treatment in these patients.
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